Turbidimetric assay to help monitor Pancreatic Exocrine Insufficiency

21. Aug 2020 | 3 min read

Turbidimetric assay to help monitor Pancreatic Exocrine Insufficiency

The newly released CE marked immunoassay BÜHLMANN fPELA® turbo is an immuno turbidimetric faecal pancreatic elastase assay for simplified quantification of human pancreatic elastase as an aid in the determination of pancreatic exocrine insufficiency (PEI).

Gentian and BÜHLMANN are the reagent provider and manufacturer for the BÜHLMANN fPELA® turbo immunoassay. The immunoassay is sold through Gentian’s partner BÜHLMANN.

 

BÜHLMANN fPELA® turbo

BÜHLMANN fPELA® turbo provides a flexible and random-access application for most available clinical chemistry platforms. With the dramatically reduced hands-on time required, this assay allows the pancreatic elastase results from human stool samples to be processed very quickly.

PEI can be caused by several underlying disorders, like chronic pancreatitis, pancreatic cancer, diabetes mellitus, and Inflammatory Bowel Disease (IBD). Consequences include diarrhea, malnutrition, and reduced Quality of Life. Hence determination of PEI and patient targeted treatment are of high importance a successful clinical outcome.

 

Same extraction buffer system for both pancreatic elastase and faecal calprotectin (BÜHLMANN fCAL® turbo)


Gentian has, in cooperation with BÜHLMANN, successfully delivered the BÜHLMANN fCAL® turbo to the market since 2016. The BÜHLMANN fCAL® turbo is the highest level automated faecal IVD test system for Inflammatory Bowel Disease (IBD) and screening of IBD vs Irritable Bowel Syndrome (IBS) on the market.

To increase diagnostic efficiency BÜHLMANN fPELA® turbo and BÜHLMANN fCAL® turbo use the same extraction buffer system, CALEX® Cap, which allows the quantitation of both analytes from the same sample preparation. Additionally, there is also an analytical and clinical advantage of the combination of p-Elastase with faecal calprotectin in the same sample. PEI and IBD may have similar symptom presentation, and therefore represents an ideal combination of markers for bowel inflammation.

Gentian Investor News 

You may also read


Gentian at AACC 2020

Nov 12, 2020

Gentian at AACC 2020

Meet us at #2020AACC Virtual Exhibit Hall  Gentian looks forward to meeting you at the AACC 2020, even it..

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

Oct 14, 2020

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

We are looking forward to sharing news and exciting things that happened in the last few months. We have for..

Webinar: Frequently asked questions about cystatin C

Oct 06, 2020

Webinar: Frequently asked questions about cystatin C

#FAQ: Cystatin C In the third webinar of the cystatin C webinar series, Shanyil Wickramasinghe, Gentian’s US..